FDA grants priority review for controversial dengue vaccine, Dengvaxia

The US FDA has accepted a Biologics License Application for Sanofi Pasteur’s (Lyon, France) dengue vaccine, Dengvaxia®, despite its controversial past.

The dengue vaccine candidate has been granted priority review by the regulatory body, as it would represent the first and only medical prevention tool against dengue – a considerable unmet need. This means a decision must be filed within 6 months.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment